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Omega-6 Fatty Acid Biomarkers and Incident Type 2 Diabetes: Pooled Analysis of
Individual-Level Data for 39 740 Adults from 20 Prospective Cohort Studies
Abstract
Background: The metabolic effects of omega-6 polyunsaturated fatty acids (PUFAs) remain contentious,
and little evidence is available regarding their potential role in primary prevention of type 2 diabetes. We
aimed to assess the associations of linoleic acid and arachidonic acid biomarkers with incident type 2
diabetes. Methods: We did a pooled analysis of new, harmonised, individual-level analyses for the
biomarkers linoleic acid and its metabolite arachidonic acid and incident type 2 diabetes. We analysed
data from 20 prospective cohort studies from ten countries (Iceland, the Netherlands, the USA, Taiwan,
the UK, Germany, Finland, Australia, Sweden, and France), with biomarkers sampled between 1970 and
2010. Participants included in the analyses were aged 18 years or older and had data available for linoleic
acid and arachidonic acid biomarkers at baseline. We excluded participants with type 2 diabetes at
baseline. The main outcome was the association between omega-6 PUFA biomarkers and incident type 2
diabetes. We assessed the relative risk of type 2 diabetes prospectively for each cohort and lipid
compartment separately using a prespecified analytic plan for exposures, covariates, effect modifiers,
and analysis, and the findings were then pooled using inverse-variance weighted meta-analysis. Findings:
Participants were 39 740 adults, aged (range of cohort means) 49-76 years with a BMI (range of cohort
means) of 23·3-28·4 kg/m(2), who did not have type 2 diabetes at baseline. During a follow-up of 366 073
person-years, we identified 4347 cases of incident type 2 diabetes. In multivariable-adjusted pooled
analyses, higher proportions of linoleic acid biomarkers as percentages of total fatty acid were
associated with a lower risk of type 2 diabetes overall (risk ratio [RR] per interquintile range 0·65, 95% CI
0·60-0·72, p

Keywords
fatty acids, omega-6, biochemical biomarkers, diabetes, cohort analysis

Disciplines
Endocrinology, Diabetes, and Metabolism

Comments
Access article on publisher's site:
10.1016/S2213-8587(17)30307-8

Authors
Jason H Y Wu, Matti Marklund, Fumiaki Imamura, Nathan L. Tintle, Andres V Ardisson Korat, Janette de
Goede, Xia Zhou, Wei-Sin Yang, Marcia C de Oliveira Otto, Janine Kroger, Waqas Qureshi, Jyrki K. Virtanen,
Julie K. Bassett, Alexis C. Frazier-Wood, Maria Lankinen, Rachel A. Murphy, Kalina Rajaobelina, Liana C.
Del Gobbo, Nita G. Forouhi, Robert Luben, Kay-Tee Khaw, Nick Wareham, Anya Kalsbeek, Jenna Veenstra,
Juhua Luo, Frank B. Hu, Hung-Ju Lin, David S. Siscovick, Heiner Boeing, Tzu-An Chen, Brian Steffen, Lyn M.
Steffen, Allison Hodge, Gudny Eriksdottir, Albert V. Smith, Vilmunder Gudnason, Tamara B. Harris,
Ingeborg A. Brouwer, Claudine Berr, Catherine Helmer, Cecilia Samieri, Markku Laakso, Michael Y. Tsai,
Graham G. Giles, Tarja Nurmi, Lynne Wagenknecht, Matthias B. Schulze, Rozenn N. Lemaitre, Kuo-Liong
Chien, Sabita S. Soedamah-Muthu, Johanna M. Geleijnse, Qi Sun, William S. Harris, Lars Lind, Johan
Arnlov, Ulf Riserus, Renata Micha, and Dariush Mozaffairian

This article is available at Dordt Digital Collections: https://digitalcollections.dordt.edu/faculty_work/822

Articles

Omega-6 fatty acid biomarkers and incident type 2 diabetes:
pooled analysis of individual-level data for 39 740 adults
from 20 prospective cohort studies
Jason H Y Wu, Matti Marklund, Fumiaki Imamura, Nathan Tintle, Andres V Ardisson Korat, Janette de Goede, Xia Zhou, Wei-Sin Yang,
Marcia C de Oliveira Otto, Janine Kröger, Waqas Qureshi, Jyrki K Virtanen, Julie K Bassett, Alexis C Frazier-Wood, Maria Lankinen, Rachel A Murphy,
Kalina Rajaobelina, Liana C Del Gobbo, Nita G Forouhi, Robert Luben, Kay-Tee Khaw, Nick Wareham, Anya Kalsbeek, Jenna Veenstra, Juhua Luo,
Frank B Hu, Hung-Ju Lin, David S Siscovick, Heiner Boeing, Tzu-An Chen, Brian Steffen, Lyn M Steffen, Allison Hodge, Gudny Eriksdottir,
Albert V Smith, Vilmunder Gudnason, Tamara B Harris, Ingeborg A Brouwer, Claudine Berr, Catherine Helmer, Cecilia Samieri, Markku Laakso,
Michael Y Tsai, Graham G Giles, Tarja Nurmi, Lynne Wagenknecht, Matthias B Schulze, Rozenn N Lemaitre, Kuo-Liong Chien,
Sabita S Soedamah-Muthu, Johanna M Geleijnse, Qi Sun, William S Harris, Lars Lind, Johan Ärnlöv, Ulf Riserus, Renata Micha, Dariush Mozaffarian;
for the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCE)

Summary

Background The metabolic effects of omega-6 polyunsaturated fatty acids (PUFAs) remain contentious, and little
evidence is available regarding their potential role in primary prevention of type 2 diabetes. We aimed to assess the
associations of linoleic acid and arachidonic acid biomarkers with incident type 2 diabetes.
Methods We did a pooled analysis of new, harmonised, individual-level analyses for the biomarkers linoleic acid and
its metabolite arachidonic acid and incident type 2 diabetes. We analysed data from 20 prospective cohort studies
from ten countries (Iceland, the Netherlands, the USA, Taiwan, the UK, Germany, Finland, Australia, Sweden, and
France), with biomarkers sampled between 1970 and 2010. Participants included in the analyses were aged 18 years
or older and had data available for linoleic acid and arachidonic acid biomarkers at baseline. We excluded participants
with type 2 diabetes at baseline. The main outcome was the association between omega-6 PUFA biomarkers and
incident type 2 diabetes. We assessed the relative risk of type 2 diabetes prospectively for each cohort and lipid
compartment separately using a prespecified analytic plan for exposures, covariates, effect modifiers, and analysis,
and the findings were then pooled using inverse-variance weighted meta-analysis.
Findings Participants were 39 740 adults, aged (range of cohort means) 49–76 years with a BMI (range of cohort
means) of 23∙3–28∙4 kg/m², who did not have type 2 diabetes at baseline. During a follow-up of 366 073 person-years,
we identified 4347 cases of incident type 2 diabetes. In multivariable-adjusted pooled analyses, higher proportions
of linoleic acid biomarkers as percentages of total fatty acid were associated with a lower risk of type 2 diabetes
overall (risk ratio [RR] per interquintile range 0∙65, 95% CI 0∙60–0∙72, p<0·0001; I²=53·9%, pheterogeneity=0·002). The
associations between linoleic acid biomarkers and type 2 diabetes were generally similar in different lipid
compartments, including phospholipids, plasma, cholesterol esters, and adipose tissue. Levels of arachidonic acid
biomarker were not significantly associated with type 2 diabetes risk overall (RR per interquintile range 0∙96,
95% CI 0∙88–1∙05; p=0∙38; I²=63·0%, pheterogeneity<0·0001). The associations between linoleic acid and arachidonic
acid biomarkers and the risk of type 2 diabetes were not significantly modified by any prespecified potential sources
of heterogeneity (ie, age, BMI, sex, race, aspirin use, omega-3 PUFA levels, or variants of the FADS gene; all
pheterogeneity≥0∙13).
Interpretation Findings suggest that linoleic acid has long-term benefits for the prevention of type 2 diabetes and
that arachidonic acid is not harmful.
Funding Funders are shown in the appendix.

Introduction
The influence of omega-6 polyunsaturated fatty acids
(PUFAs), in particular linoleic acid—the predominant
omega-6 PUFA—on health remains disputed.1,2 Most
major guidelines, including those from the American
Heart Association and Dietary Guidelines for Ameri
cans,3,4 recommend that 5–10% of energy is obtained
from linoleic acid, which is primarily derived from
vegetable oils. However, some researchers have hypo

thesised that linoleic acid might be harmful because
it competes with omega-3 PUFA or because its
metabolite arachidonic acid might have harmful
effects.5,6 In response to such concerns, French national
guidelines7 have recommended limiting linoleic acid
consumption to no more than 4% of energy.
Although many studies4,8 have investigated the
cardiovascular effects of omega-6 PUFAs, less is known
about their influence on other major outcomes, such as
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Research in context
Evidence before this study
We searched MEDLINE from inception to Feb 10, 2016, using
the search terms “omega-6”, “linoleic acid”, “arachidonic
acid”, “diabetes mellitus”, “cohort studies”, “prospective
studies”, and “nested case control studies”, for articles
published in English, manually searched reference lists of
previous original publications and systematic reviews, and
contacted experts to identify prospective observational
studies that assessed the association between linoleic acid
(the main dietary omega-6 polyunsaturated fat) and its
downstream metabolite, arachidonic acid, and the risk of
incident type 2 diabetes. We identified few previous studies
that had investigated the association between linoleic acid
and arachidonic acid biomarkers and type 2 diabetes; most
relied on estimated levels of consumption from self-reported
questionnaires, for which evidence has been considered weak.
Although biomarkers of linoleic acid and arachidonic acid
offer objective assessment of exposure that is free of recall
bias, only a handful of prospective studies have evaluated
associations between linoleic acid or arachidonic acid
biomarkers and type 2 diabetes, with potential limitations of
publication bias, and inadequate power to evaluate
interactions by population characteristics.
Added value of this study
We did a new, harmonised analysis of individual-level data
from 20 prospective cohort studies to assess the association
between levels of linoleic acid and arachidonic acid
biomarkers and the risk of incident type 2 diabetes. Data from
366 703 person-years of follow-up of more than
39 000 adults without type 2 diabetes at baseline showed a
linear inverse association between levels of the biomarker

type 2 diabetes. A meta-analysis9 of randomised controlled
feeding trials indicated that total PUFA consumption
(predominantly linoleic acid) improves both glycaemia
and insulin resistance. However, whether such short-term
benefits translate to primary prevention of type 2 diabetes
remains unclear. Most longitudinal studies10 of linoleic
acid and incident type 2 diabetes have relied on selfreported dietary estimates of intake that might be affected
by errors or bias in recall. Linoleic acid cannot be
synthesised by human beings, and thus biomarker
measurements of linoleic acid can provide objective
assessments that are free of memory errors, recall bias, or
inaccuracies of food databases.11 Biomarker measurements
are also crucial for studying the effects of arachidonic acid,
for which levels are tightly regulated and less correlated
with dietary intake.12 However, only a handful of pro
spective studies10 have evaluated associations be
tween
linoleic acid or arachidonic acid biomarkers and type 2
diabetes, resulting in potential limitations of publication
bias and inadequate power to assess inter
actions by
demographic, medical, or genetic characteristics. Thus,

linoleic acid and the incidence of type 2 diabetes, with similar
findings across different lipid compartments. Conversely,
overall levels of the biomarker arachidonic acid were not
significantly associated with type 2 diabetes. To the best of
our knowledge, this is the largest and most detailed
assessment of objective biomarkers of omega-6
polyunsaturated fatty acids and the incidence of type 2
diabetes. The breadth and scope of the cohorts allowed
further assessment of heterogeneity. Despite the diversity of
the 20 contributing cohorts, evidence did not indicate that
the associations differed by age, BMI, sex, race, omega-3
polyunsaturated fatty acid levels, aspirin use, or variation in
the genes encoding fatty acid desaturase.
Implications of all the available evidence
The prevalence of type 2 diabetes is escalating rapidly around
the world, so identification of dietary and other modifiable
risk factors for the prevention of the disease is of clinical,
scientific, and public health importance. Several dietary
guidelines recommend increased linoleic acid consumption to
improve blood cholesterol levels and reduce cardiovascular
risk. Our analysis provides novel findings that, when
combined with in-vitro experimental and shorter-term
interventions for metabolic risk factors, suggest that linoleic
acid has an additional role for prevention of type 2 diabetes in
healthy populations. Additionally, our findings do not
corroborate concerns about potential harmful effects of
arachidonic acid. Consistent with these findings, a recent
systematic review found that levels of the biomarker
arachidonic acid were associated with lower incidence of
coronary heart disease.

the potential effects of omega-6 PUFAs, including
linoleic acid and its metabolite arachidonic acid, on type 2
diabetes remain unresolved and are of considerable
clinical, scientific, and public health importance. To
address these questions, we did a pooled analysis of new,
harmonised, individual-level data within the Fatty Acids
and Outcomes Research Consortium.13 Our primary aim
was to assess the associations of linoleic acid and arach
idonic acid biomarkers with incident type 2 diabetes, with
additional aims to assess factors that might modify
these associations. We hypothesised that the level of
linoleic acid biomarkers, but not arachidonic acid bio
markers, would be inversely associated with type 2 diabetes
risk.

Methods

Study population
In this pooled analysis, we identified prospective co
hort studies that had assessed circulating or tissue

biomarkers of linoleic acid and arachidonic acid, and
incidence of type 2 diabetes. Studies were identified by
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contacting experts, manual searches of reference lists of
previous original publications and systematic reviews,
and online searches of MEDLINE from inception to
Feb 10, 2016, using the search terms “omega-6”, “linoleic
acid”, “arachidonic acid”, “diabetes mellitus”, “cohort
studies”, “prospective studies”, and “nested case control
studies”.
Participants included in the analysis were aged 18 years
or older, with available data for linoleic acid and arachidonic
acid biomarkers at baseline. Participants with type 2 dia
betes at baseline were excluded. Each cohort receieved
institutional review board approval from their respective
institutions and written consent was obtained from all
participants.

Uniform analysis protocol
A standardised analysis protocol was developed and
provided to researchers for each participating cohort.
To reduce heterogeneity, the analysis plan included
harmonised specifications for population inclusion,
exposures, covariates, effect modifiers, outcomes, and
analysis, and specifications for methods for pooling
results. Individual scientists analysed individual-level
data from each cohort and provided the results using
prespecified standardised electronic forms, which were
sent to JHYW for pooling.

Procedures
Fatty acid levels were assessed in each study in various
lipid compartments and expressed as the proportion of
total fatty acids (appendix).
Incident type 2 diabetes was defined by whichever of
the following criteria were met first: a fasting glucose
concentration of 126 mg/dL (7·0 mmol/L) or higher,
a glucose concentration of 200 mg/dL (11·1 mmol/L) or
higher as measured by a 2 h post-oral glucose tolerance
test, new use of insulin or oral hypoglycaemic medi
cation, fasting or non-fasting HBA1c concentrations of
6∙5% or more, or by self-reported physician diagnosis in
some cohorts (appendix).
On the basis of biological interest and well established
associations with type 2 diabetes risk, prespecified
covariates were age, sex, race, site of patient recruitment if
applicable, BMI, education, smoking, physical activity,
alcohol intake, prevalent coronary heart disease, treatment
for hypertension, treatment for hypercholesterolaemia,
and biomarker omega-3 PUFA concentrations (appendix).
Participants with missing categorical covariates were inc
luded via missing indicator categories.
To minimise concerns about multiple testing, we pre
specified all potential sources of heterogeneity on the
basis of demographic, anthropometric, or biological im
portance. Cohort-specific analyses were stratified by age,
sex, race, BMI, long-chain omega-3 PUFA biomarker
concentrations, aspirin use (which might promote
formation of arachidonic acid-derived resolvers of inflam
mation), and common genetic variations in the fatty acid

desaturase (FADS) genes (ie, FADS1 [single nucleotide
polymorphism rs174547]), which most strongly associates
with omega-6 PUFA levels (appendix).14

Cohort analyses
For prospective cohorts with time-to-event data, Cox
proportional hazards were used to obtain the hazard ratio
(HR) and SE. For studies with a case-cohort design,
weighted Cox models were used.15 Participants were
followed up from time of fatty acid measurement to time
of diagnosis of type 2 diabetes, death, or censoring at the
end of follow-up. For a prospective case-cohort16 and
prospective case-control study17 without time-to-event
data, logistic regression (weighted for case-cohort studies)
was used to obtain the odds ratio (OR) and SE for incident
type 2 diabetes. All analyses used robust SEs.
To reduce likelihood of reverse causation as a result of
prevalent subclinical disease, sensitivity analyses were
done in each cohort, excluding cases diagnosed in the
first 2 years of follow-up. To minimise exposure mis
classification due to changes in fatty acid levels over time,
we also did a sensitivity analysis for each cohort, censoring
participants after the initial 6 years of follow-up.

Data pooling and meta-analysis
We used HRs and ORs to approximate relative risks
(RRs) and pooled the data to generate summary results
using inverse-variance weighted meta-analysis. We also
used random effects models in sensitivity analyses.18
Because fatty acids were measured in different lipid
compartments (phospholipids, plasma, cholesterol esters,
and adipose tissue) using differing methods, linoleic
acid and arachidonic acid were evaluated continuously
per study-specific interquintile range (the distance
between the midpoint of the first and fifth quintiles) to
facilitate pooling. We pooled results separately for each
lipid compartment and across all studies. For studies
with multiple measures, we prioritised the overall pooled
analysis on the basis of the biomarkers that would best
reflect long-term intake, as specified in the following
ordered list: adipose tissue, erythrocyte phospholipids,
plasma phos
pholipids, total plasma or serum, and
cholesterol esters.12
We assessed potential non-linear relationships by
pooling the HR or OR for each study-specific quintile,
established as an indicator variable against the lowest
quintile as the reference; and in each compartment by
multivariate inverse-variance weighted meta-regression,
modelling the fatty acid quintile results using restricted
cubic splines.19,20 Because findings across compartments
could not be pooled using restricted cubic splines, these
analyses were considered exploratory. Heterogeneity was
assessed using the I² statistic. Statistical significance of
differences between prespecified subgroups was assessed
using inverse-variance weighted meta-regression. We
used STATA (version 13.1) with a two-sided α level of
0·05 for all meta-analyses.
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Country

Baseline year(s) of Study
blood sampling
design

Number of
participants
(n)

Number of men Age (years)
(%)

BMI
(kg/m²)

Biomarker compartment
assessed

Incident type 2 Maximum
diabetes cases follow-up
(n)
(years)

AGES-Reykjavik

Iceland

2002–06

PC

753

309 (41%)

76 (5·2)

27 (4)

Plasma phospholipids

28

7·8

AOC

Netherlands

2002–06

PC

2888

2282 (79%)

69 (5·6)

27 (4)

Cholesterol esters

154

4·8

ARIC

USA

1987–89

PC

3494

1642 (47%)

54 (5·6)

27 (4)

Plasma phospholipids

304

9·0

CCCC

Taiwan

1992–93

PC

616

370 (60%)

59 (9·9)

23 (3)

Total plasma

128

8·1

CHS

USA

1992–93

PC

3179

1240 (39%)

72 (5·2)

26 (5)

Plasma phospholipids

284

18·0

EPIC-Norfolk

UK

1993–97

PCC

383

203 (53%)

64 (8·1)

28 (4)

Erythrocyte phospholipids,
plasma phospholipids

199

12·1

EPIC-Potsdam

Germany

1994–98

PNC

2165

823 (38%)

49 (8·9)

26 (4)

Erythrocyte phospholipids

488

10·1

FHS

USA

2005–08

PC

1913

823 (43%)

64 (8·3)

28 (5)

Erythrocyte phospholipids

98

9·0

HPFS

USA

1994

PC

1545

1545 (100%)

65 (8·6)

26 (3)

Erythrocyte phospholipids,
Total plasma

113

17·6

IRAS

USA

1992–94

PC

719

316 (44%)

55 (8·5)

28 (6)

Total plasma

146

5·0

KIHD

Finland

1991–92 (men)
2003 (women)

PC

3145

2327 (74%)

56 (7·1)

27 (4)

Serum

595

26·8

MCCS

Australia

1990–94

PNC

4046

1821 (45%)

55 (8·6)

27 (5)

Plasma phospholipids

336

9·9

MESA

USA

2000–02

PC

2230

1026 (46%)

61 (10·1)

28 (5)

Plasma phospholipids

297

11·2

METSIM

Finland

2006–10

PC

1301

1301 (100%)

55 (5·6)

26 (3)

Cholesterol esters,
erythrocyte phospholipids,
plasma phospholipids

71

7·9

NHS

USA

1990

PC

1595

60 (6·4)

25 (4)

Erythrocyte phospholipids,
total plasma

154

22·8

PIVUS

Sweden

2001–04

PC

861

422 (49%)

70 (0·2)

27 (4)

Cholesterol esters, plasma
phospholipids

69

10·9

3C

France

1999–00

PC

1220

464 (38%)

74 (4·8)

26 (4)

Erythrocyte phospholipids,
total plasma

36

13·0

246

42·3

0

ULSAM-50

Sweden

1970–73

PC

1891

1891 (100%)

50 (0·6)

25 (3)

Cholesterol esters

ULSAM-70

Sweden

1991–95

PC

738

738 (100%)

71 (0·6)

26 (3)

Adipose tissue

WHIMS

USA

1996

PC

5799

70 (3·8)

28 (5)

Erythrocyte phospholipids

0

99

21·5

502

14·1

Data are n, n (%), or mean (SD), unless otherwise specified. Characteristics were correct at the time of fatty acid biomarker measurement. References for all studies are shown in the appendix. AGES-Reykjavik=Age,
Gene/Environment Susceptibility Study (Reykjavik). AOC=Alpha Omega Cohort. ARIC=Atherosclerosis Risk in Communities. CCCC=Chin-Shan Community Cardiovascular Cohort Study. CHS=Cardiovascular Health
Study. EPIC-Norfolk=European Prospective Investigation into Cancer (Norfolk). EPIC-Potsdam=European Prospective Investigation into Cancer (Potsdam). FHS=Framingham Heart Study. HPFS=Health Professionals
Follow-up Study. IRAS=Insulin Resistance Atherosclerosis Study. KIHD=Kuopio Ischaemic Heart Disease Risk Factor Study. MCCS=Melbourne Collaborative Cohort Study. MESA=Multi-Ethnic Study of Atherosclerosis.
METSIM=Metabolic Syndrome in Men Study. NHS=Nurses’ Health Study. PIVUS=Prospective Investigation of the Vasculature in Uppsala Seniors. 3C=Three City Study. ULSAM-50=Uppsala Longitudinal Study of Adult
Men-50. ULSAM-70=Uppsala Longitudinal Study of Adult Men-70. WHIMS=Women’s Health Initiative Memory Study. PC=prospective cohort. PCC=prospective nested case-control. PNC=prospective nested
case-cohort.

Table 1: Baseline cohort characteristics from 20 studies with linoleic acid and arachidonic acid biomarker measures and follow-up data for incident type 2 diabetes

Role of the funding source
The funders of the study had no role in study design,
data collection, data analysis, writing of the report, or the
decision to submit for publication. The corresponding
author had full access to all the data. All authors had final
responsibility for the decision to submit for publication.

Results
20 (77%) of the 26 studies identified agreed to participate
by February, 2016. Overall, we included 39 740 adults from
20 cohorts in ten countries (USA, Iceland, the Netherlands,
Germany, Finland, the UK, Sweden, France, Australia, and
Taiwan) in the analyses. Participants with missing
continuous covariates were excluded (maximum exclusion
for an individual covariate was 3·3%). Our analyses
included 17 prospective cohort studies, two prospective
case-cohort studies, and one nested case-control cohort
study. Table 1 shows the baseline characteristics of the
4

studies and the participants. The ranges of the mean
cohort ages (49–76 years) and BMI (23·3–28·4 kg/m²)
were wide. Within cohorts, even wider age ranges and BMI
ranges were represented (appendix). Most participants
were of European descent, although several cohorts
included greater than 10% of individuals of African
(Insulin Resistance Atherosclerosis Study [IRAS; 24·5%],
Multi-Ethnic Study of Atherosclerosis [MESA; 23·9%],
Cardiovascular Health Study [11·1%]), Asian (Chin-Shan
Community Cardiovascular Cohort Study [100%],
MESA [25·6%]), or Hispanic (IRAS [33·2%], MESA [22·2%])
descent (appendix).
Fatty acid biomarkers were measured in phospholipids
(n=14 cohorts), total plasma or serum (n=6), cholesterol
esters (n=4), and adipose tissue (n=1); and in six cohorts,
measurements were done in more than two lipid
compartments. With the exception of the Uppsala
Longitudinal Study of Adult Men-50 (1970–73) cohort,
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Studies
(n)†

Cases
(n)†

Continuous analysis‡

Quintile 5 vs quintile 1

I² (%)

Relative risk fixed effect

Relative risk random effect

I² (%)

Relative risk fixed effect

Relative risk random effect

Linoleic acid
Phospholipids

14

2979

58·4%

0·69 (0·61–0·77)

0·64 (0·53–0·78)

56·3%

0·60 (0·52–0·70)

0·57 (0·45–0·72)

Total plasma or serum

6

1220

40·7%

0·55 (0·47–0·64)

0·55 (0·44–0·69)

1·0%

0·47 (0·38–0·59)

0·47 (0·38–0·59)

Cholesterol esters

4

624

0%

0·58 (0·46–0·73)

0·58 (0·46–0·73)

0%

0·54 (0·41–0·73)

0·54 (0·41–0·73)

Adipose tissue

1

99

··

0·82 (0·49–1·35)

0·82 (0·49–1·35)

..

0·76 (0·38–1·53)

0·76 (0·38–1·53)

20

4347

53·9%

0·65 (0·60–0·72)

0·64 (0·56–0·74)

46·3%

0·57 (0·51–0·64)

0·57 (0·48–0·67)

Overall
Arachidonic acid

14

2979

64·2%

0·99 (0·89–1·10)

1·01 (0·84–1·22)

54·6%

0·99 (0·86–1·14)

0·97 (0·78–1·22)

Total plasma or serum

Phospholipids

6

1220

63·8%

0·73 (0·62–0·86)

0·74 (0·54–1·03)

66·5%

0·64 (0·52–0·79)

0·65 (0·43–0·99)

Cholesterol esters

4

624

12·3%

1·12 (0·90–1·40)

1·14 (0·90–1·46)

0%

1·22 (0·94–1·59)

1·22 (0·94–1·59)

Adipose tissue

1

99

··

1·56 (0·84–2·89)

1·56 (0·84–2·89)

..

1·67 (0·72–3·91)

1·67 (0·72–3·91)

20

4347

63·0%

0·96 (0·88–1·05)

1·01 (0·87–1·18)

0·93 (0·83–1·04)

0·96 (0·79–1·17)

Overall

61·2%

Data are relative risk (95% CI). *Effect estimates were pooled using inverse-variance weighted or random effects meta-analysis. †Multiple biomarkers were available in some studies, but only one biomarker per
study was included for estimation of overall relative risks, therefore the overall number of studies and cases does not equal the sum of studies and cases per biomarker. ‡Fatty acids were modelled as continuous
variables and relative risks were estimated per interquintile range (ie, the distance between the midpoints of the first and fifth quintiles).

Table 2: Pooled relative risks of type 2 diabetes according to levels of linoleic acid and arachidonic acid biomarkers*

baseline blood was sampled between 1987–89 and
2002–06. All studies used gas chromatography to measure
fatty acid biomarkers, with interassay co
efficients of
variation less than or equal to 15% (appendix). The median
percentage of linoleic acid in total fatty acid in each cohort
ranged from 8·3% in erythrocyte phospholipids to 54·5%
in plasma cholesterol esters (appendix). The median
percentage of arachidonic acid in total fatty acid ranged
from 0·3% in adipose tissue to 17·0% in erythrocyte
phospholipids (appendix). Spearman correlations across
lipid compartments within the six studies that included
more than one measure ranged from 0·38 to 0·84 for
linoleic acid and from 0·48 to 0·92 for arachidonic acid
(appendix).
During 366 073 person-years, 4347 participants
developed type 2 diabetes (appendix). In pooled analyses,
linoleic acid levels were inversely associated with incidence
of type 2 diabetes, with a lower risk in continuous analyses
per interquintile range (fixed-effect RR 0·65, 95% CI
0·60–0·72, p<0·0001) and in categorical analysis
(quintile 5 vs quintile 1; 0·57, 0·51–0·64, p<0·0001;
table 2). Findings were similar across lipid compartments
(figure 1; table 2), although not statistically significant in
adipose tissue, for which only one study provided data
(99 incident cases out of 738 participants). Heterogeneity
in the overall pooled analysis was moderate (I²=53·9% for
continuous analyses, 46·3% for categorical analyses;
table 2).
Arachidonic acid biomarkers were not associated with
incidence of type 2 diabetes overall (RR per interquintile
range 0·96, 95% CI 0·88–1·05, p=0·38; table 1, figure 2).
Arachidonic acid biomarker concentrations in separate
lipid compartments were not associated with type 2
diabetes, with the exception of total plasma, whereby an
inverse association was identified (RR per interquintile

range 0·73, 95% CI 0·62–0·86, p=0·0003; I²=63∙8%;
table 1, figure 2).
Categorical analysis across quintiles showed that
participants in each of the higher quintiles (2–5) of linoleic
acid biomarker had significantly lower risk than
participants within the lowest quintile (figure 3).
Additionally, the dose–response association between
linoleic acid biomarker and type 2 diabetes appeared
monotonic (appendix).
Restricted cubic spline regression analysis within each
lipid compartment found little evidence for non-linearity in
the relationship between linoleic acid biomarkers in
cholesterol esters or total plasma and incident type 2 dia
betes (pnon-linearity≥0·4 each; plinearity<0·001 each; appendix).
A potentially non-linear association was identified in
erythrocyte phospholipids (pnon-linearity=0·005) and plasma
phospholipids (pnon-linearity=0·03; appendix); risk for each
association declined steeply initially then plateaued (but did
not significantly increase) at very high levels. For
arachidonic acid, levels of biomarker in total plasma were
associated with lower risk (plinearity<0·001), with little
evidence for non-linear asso
ciations within any of the
compartments (pnon-linearity≥0·47; appendix). Although overall
arachidonic acid biomarker levels in phospholipids were
not associated with type 2 diabetes (table 2, figure 2),
exploratory restricted cubic spline analyses, which assessed
erythrocyte phospholipids (plinearity=0·001) and plasma
phospholipids (plinearity=0·03) separately, suggested divergent
linear associations with type 2 diabetes (appendix).
The associations of linoleic acid and arachidonic acid
biomarkers with incident type 2 diabetes did not
significantly vary according to any prespecified potential
sources of heterogeneity (pheterogeneity≥0·13 each; appendix).
In the 12 cohorts with available genetic data, genetic
variants of the FADS genes had no significant interaction
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on the association between either linoleic acid or
arachidonic acid biomarker levels and incident type 2
diabetes (pinteraction≥0·47; appendix).
Compared with the main analyses, similar results were
observed for linoleic acid and arachidonic acid biomarkers
after exclusion of type 2 diabetes cases identified in the
first 2 years of follow-up, and censoring of follow-up at
6 years after baseline (appendix).

Discussion
In this consortium of 20 prospective studies across
ten countries, biomarker levels of linoleic acid were
Total (n)

Type 2 diabetes
cases (n)

RR (95% CI)

Phospholipid
AGES−Reykjavik
METSIM
MCCS
FHS
3C
EPIC−Norfolk
EPIC−Potsdam
ARIC
CHS
PIVUS
MESA
HPFS
WHIMS
NHS
Overall

753
1301
4046
1913
574
383
2165
3494
3179
861
2230
1545
5799
1500
I2=58·4%

28
71
336
98
36
199
488
304
284
69
297
113
502
154
p=0·003 for heterogeneity

0·27 (0·08–0·91)
0·29 (0·14–0·59)
0·36 (0·24–0·55)
0·48 (0·26–0·90)
0·51 (0·19–1·37)
0·56 (0·31–1·00)
0·62 (0·44–0·87)
0·65 (0·49–0·88)
0·66 (0·46–0·95)
0·70 (0·26–1·86)
0·81 (0·58–1·14)
0·81 (0·58–1·15)
0·89 (0·67–1·17)
1·15 (0·77–1·70)
0·69 (0·61–0·77)

Total plasma
HPFS
NHS
KIHD
IRAS
3C
CCCC
Overall

1497
1595
3145
719
1220
616
I2=40·7%

109
159
595
146
83
128
p=0·134 for heterogeneity

0·42 (0·26–0·69)
0·44 (0·30–0·64)
0·54 (0·43–0·68)
0·56 (0·33–0·95)
0·57 (0·34–0·94)
1·03 (0·62–1·69)
0·55 (0·47–0·64)

Cholesterol ester
METSIM
ULSAM-50
AOC
PIVUS
Overall

1301
1891
2888
822
I2=0%

71
332
154
67
p=3·863 for heterogeneity

0·50 (0·28–0·91)
0·57 (0·41–0·79)
0·58 (0·37–0·93)
0·80 (0·34–1·87)
0·58 (0·46–0·73)

Adipose tissue
ULSAM-70
Overall
AGES−Reykjavik
METSIM
MCCS
FHS
ULSAM-50
3C
KIHD
EPIC−Norfolk
IRAS
AOC
EPIC−Potsdam
ARIC
CHS
PIVUS
MESA
HPFS
ULSAM-70
WHIMS
CCCC
NHS
Overall

738
753
1301
4046
1913
1891
574
3145
383
719
2888
2165
3494
3179
861
2230
1545
738
5799
616
1500
I2=53·9%

99

0·82 (0·49–1·35)

28
71
336
98
246
36
595
199
146
154
488
304
284
69
297
113
99
502
128
154
p=0·002 for heterogeneity
0·2

6

0·27 (0·08–0·91)
0·29 (0·14–0·59)
0·36 (0·24–0·55)
0·48 (0·26–0·90)
0·49 (0·34–0·71)
0·51 (0·19–1·37)
0·54 (0·43–0·68)
0·56 (0·31–1·00)
0·56 (0·33–0·95)
0·58 (0·37–0·93)
0·62 (0·44–0·87)
0·65 (0·49–0·88)
0·66 (0·46–0·95)
0·70 (0·26–1·86)
0·81 (0·58–1·14)
0·81 (0·58–1·15)
0·82 (0·49–1·35)
0·89 (0·67–1·17)
1·03 (0·62–1·69)
1·15 (0·77–1·70)
0·65 (0·60–0·72)
0·5

1·0

1·5

inversely associated with incident type 2 diabetes, whereas
levels of arachidonic acid biomarkers were not associated
with type 2 diabetes. The magnitude of the association
between linoleic acid biomarkers and type 2 diabetes was
substantial, with high linoleic acid levels associated with a
43% lower relative risk of type 2 diabetes across quintiles
in the categorical analysis. To the best of our knowledge,
this is the largest and most detailed biomarker assessment
of omega-6 PUFA and type 2 diabetes, including across
multiple lipid compartments. Despite the breadth and
scope of the cohorts, associations did not seem to differ
by age, BMI, sex, race, omega-3 PUFA levels, aspirin use,
or variation in the genes encoding FADS.
Incorporation of linoleic acid into phospholipids alters
membrane fluidity and might modulate insulin receptor
activity.21 In a meta-analysis9 of 102 randomised controlled
feeding trials, dietary PUFAs (predominantly linoleic
acid) improved glycaemia, insulin resistance, and
insulin secretion capacity, compared with carbohydrate,
saturated fat, and for some endpoints even mono
unsaturated fat. In other randomised controlled trials,22
linoleic acid-rich vegetable oil reduced markers of inflam
mation, visceral fat deposition, and hepatic steatosis.
Because dietary linoleic acid intake correlates with levels
of circulating and tissue linoleic acid,12 our biomarkerbased findings extend and expand these previous results
by providing evidence that linoleic acid might have longterm benefits for preventing the onset of type 2 diabetes,
supporting clinical recommendations to increase dietary
intake of linoleic acid-rich vegetable oils. Our novel
findings also support the need for future studies to
establish the potential influence and clinical effects of
other influences (eg, pharmacological) on these fatty acid
biomarkers, identify the downstream biological me
diating pathways of these fatty acid biomarkers on risk of
type 2 diabetes, and investigate potential novel influences
Figure 1: Pooled relative risks of type 2 diabetes according to interquintile
range* of linoleic acid biomarker, per lipid compartment
The association between linoleic acid and type 2 diabetes was assessed in
multivariable models for each cohort, and the results were pooled using
inverse-variance weighted fixed effects meta-analysis. If multiple biomarkers
were available within a study, one was chosen for the overall analysis on the
basis of its ability to reflect long-term dietary intake (in the following order of
preference): adipose tissue, phospholipids, total plasma, and cholesterol esters.
Similarly, data for erythrocyte phospholipids were preferred over plasma
phospholipids if both were available from a cohort. References for all studies are
shown in the appendix. RR=relative risk. AGES-Reykjavik=Age,
Gene/Environment Susceptibility Study (Reykjavik). METSIM=Metabolic
Syndrome in Men Study. MCCS=Melbourne Collaborative Cohort Study.
FHS=Framingham Heart Study. 3C=Three City Study. EPIC-Norfolk=European
Prospective Investigation into Cancer (Norfolk). EPIC-Potsdam=European
Prospective Investigation into Cancer (Potsdam). ARIC=Atherosclerosis Risk in
Communities. CHS=Cardiovascular Health Study. PIVUS=Prospective
Investigation of the Vasculature in Uppsala Seniors. MESA=Multi-Ethnic Study of
Atherosclerosis. HPFS=Health Professionals Follow-up Study. WHIMS=Women’s
Health Initiative Memory Study. NHS=Nurses’ Health Study. KIHD=Kuopio
Ischaemic Heart Disease Risk Factor Study. IRAS=Insulin Resistance
Atherosclerosis Study. CCCC=Chin-Shan Community Cardiovascular Cohort
Study. ULSAM-50=Uppsala Longitudinal Study of Adult Men-50. AOC=Alpha
Omega Cohort. ULSAM-70=Uppsala Longitudinal Study of Adult Men-70.
*Difference between the midpoints of the first and fifth quintiles.
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(eg, pharmacological and lifestyle) on these downstream
biological mediating pathways. Mendelian random
isation studies23 should also assess the association
between the common genetic variants that influence
fatty acid concentrations and type 2 diabetes.
Despite the established benefits of PUFAs for blood
cholesterol levels and glucose-insulin homoeostasis,9
some scientists maintain that omega-6 PUFA is harmful
for health.24 A main theorised harm relates to the
conversion of linoleic acid to arachidonic acid, which has
been considered as pro-inflammatory and potentially
harmful for glucose metabolism, weight regulation, and
eating behaviour.6 However, multiple studies indicate
that variations in both dietary linoleic acid and
arachidonic acid have little effect on circulating
arachidonic acid levels, indicating close endogenous
regulation of the metabolite.25 Additionally, arachidonic
acid has important metabolites that actively resolve
inflammation,26 and systematic reviews of trials have not
identified pro-inflammatory effects of linoleic acid
consumption.27 Indeed, a systematic review8 found that
higher biomarker levels of arachidonic acid were
associated with lower incidence of coronary heart disease.
We found no evidence to suggest that arachidonic acid
contributes to the development of type 2 diabetes.
Together with the findings of previous experimental and
interventional studies on metabolic risk factors, our
findings do not suggest that high levels of dietary
omega-6 PUFA are harmful. Additionally, although
omega-3 and omega-6 PUFA has been hypothesised to
compete, we did not identify any evidence of a
physiologically relevant inter
action in this large, well
powered consortium analysis.
A 2016 nested case-cohort analysis from the European
Prospective Investigation into Cancer (EPIC) cohort,28
published during the preparation of our manuscript,
Figure 2: Pooled relative risks of type 2 diabetes according to interquintile
range* of arachidonic acid biomarker, per lipid compartment
Association between arachidonic acid and type 2 diabetes was assessed in
multivariable models for each cohort, and the results were pooled using
inverse-variance weighted fixed effects meta-analysis. If multiple biomarkers
were available within a study, one was chosen for the overall analysis on the
basis of its ability to reflect long-term dietary intake (in the following order of
preference): adipose tissue, phospholipids, total plasma, and cholesterol esters.
Similarly, data for erythrocyte phospholipids was preferred over plasma
phospholipids if both were available from a cohort. References for all studies are
shown in the appendix. RR=relative risk. HPFS=Health Professionals Follow-up
Study. EPIC-Potsdam=European Prospective Investigation into Cancer
(Potsdam). NHS=Nurses’ Health Study. WHIMS=Women’s Health Initiative
Memory Study. FHS=Framingham Heart Study. EPIC-Norfolk=European
Prospective Investigation into Cancer (Norfolk). MCCS=Melbourne
Collaborative Cohort Study. 3C=Three City Study. PIVUS=Prospective
Investigation of the Vasculature in Uppsala Seniors. MESA=Multi-Ethnic Study
of Atherosclerosis. ARIC=Atherosclerosis Risk in Communities.
CHS=Cardiovascular Health Study. AGES-Reykjavik=Age, Gene/Environment
Susceptibility Study (Reykjavik). METSIM=Metabolic Syndrome in Men Study.
IRAS=Insulin Resistance Atherosclerosis Study. KIHD=Kuopio Ischaemic Heart
Disease Risk Factor Study. CCCC=Chin-Shan Community Cardiovascular Cohort
Study. ULSAM-50=Uppsala Longitudinal Study of Adult Men-50. AOC=Alpha
Omega Cohort. ULSAM-70=Uppsala Longitudinal Study of Adult Men-70.
*Difference between the midpoints of the first and fifth quintiles.

found an inverse association between plasma phos
pholipid linoleic acid and type 2 diabetes (HR per SD
increase 0·80, 95% CI 0·77–0·83), and no significant
association between arachidonic acid and type 2 diabetes
(HR 1·02, 0·98–1·06). Our findings are consistent with
this report, and include a worldwide perspective, using
data from multiple lipid compartments and detailed
assessment of potential effect modification, including by
variation in the genes encoding FADS. Our study also
Total (n)

Type 2 diabetes
cases (n)

Phospholipid
HPFS
EPIC−Potsdam
Phospholipid
NHS
HPFS
WHIMS
EPIC−Potsdam
FHS
NHS
EPIC−Norfolk
WHIMS
MCCS
FHS
3C
EPIC−Norfolk
PIVUS
MCCS
MESA
3C
ARIC
PIVUS
CHS
MESA
AGES−Reykjavik
ARIC
METSIM
CHS
Overall
AGES−Reykjavik

Total (n)
1545
2165
1500
1545
5799
2165
1913
1500
383
5799
4046
1913
574
383
861
4046
2230
574
3494
861
3179
2230
753
3494
1301
3179
2
I =64·2%
753

Type 2 diabetes
cases
113 (n)
488
154
113
502
488
98
154
199
502
336
98
36
199
69
336
297
36
304
69
284
297
28
304
71
284
p=0·001
for heterogeneity
28

CCCC
Cholesterol ester
Overall
ULSAM-50
AOC
Cholesterol ester
PIVUS
ULSAM-50
METSIM
AOC
Overall
PIVUS

616
I2=63·8%
1891
2888
822
1891
1301
2888
I2822
=12·3%

1301
I2=64·2%
1497
1595
719
1497
3145
1595
1220
719
616
3145
2
I1220
=63·8%

METSIM
Adipose
Overall tissue
ULSAM-70

1301
I2=12·3%
738

71
p=0·331 for heterogeneity
99

Adipose tissue
Overall
ULSAM-70
HPFS
IRAS
Overall
KIHD
HPFS
EPIC−Potsdam
IRAS
NHS
KIHD
WHIMS
EPIC−Potsdam
FHS
NHS
EPIC−Norfolk
WHIMS
MCCS
FHS
ULSAM-50
EPIC−Norfolk
AOC
MCCS
3C
ULSAM-50
PIVUS
AOC
MESA
3C
ARIC
PIVUS
CHS
MESA
AGES−Reykjavik
ARIC
ULSAM-70
CHS
CCCC
AGES−Reykjavik
METSIM
ULSAM-70
Overall
CCCC

738
1545
719
3145
1545
2165
719
1500
3145
5799
2165
1913
1500
383
5799
4046
1913
1891
383
2888
4046
574
1891
861
2888
2230
574
3494
861
3179
2230
753
3494
738
3179
616
753
1301
738
2
I =63·0%
616

99
113
146
595
113
488
146
154
595
502
488
98
154
199
502
336
98
246
199
154
336
36
246
69
154
297
36
304
69
284
297
28
304
99
284
128
28
71
99
p<0·0001
for heterogeneity
128

1301
I2=63·0%

RR (95% CI)
0·45 (0·30–0·69)
0·76 (0·57–1·01)
0·78 (0·50–1·24)
0·45
(0·30–0·69)
0·79 (0·59–1·05)
0·76
(0·57–1·01)
0·93 (0·50–1·24)
(0·52–1·68)
0·78
1·00 (0·62–1·63)
0·79
(0·59–1·05)
1·01
(0·73–1·38)
0·93 (0·52–1·68)
1·21
1·00 (0·51–2·86)
(0·62–1·63)
1·25
1·01 (0·71–2·19)
(0·73–1·38)
1·25
(0·89–1·75)
1·21 (0·51–2·86)
1·30
(0·96–1·76)
1·25 (0·71–2·19)
1·42
(1·04–1·95)
1·25 (0·89–1·75)
1·51
1·30 (0·64–3·56)
(0·96–1·76)
2·17
1·42 (1·03–4·57)
(1·04–1·95)
0·99
(0·89–1·10)
1·51 (0·64–3·56)

71
p=0·001 for heterogeneity
109
159
146
109
595
159
83
146
128
595
p=0·017
for heterogeneity
83

METSIM
Total
plasma
Overall
HPFS
NHS
Total plasma
IRAS
HPFS
KIHD
NHS
3C
IRAS
CCCC
KIHD
Overall
3C

METSIM
Overall

RR (95% CI)

2·17 (1·03–4·57)
0·99 (0·89–1·10)
0·38 (0·22–0·68)
0·67 (0·41–1·10)
0·69
(0·38–1·28)
0·38 (0·22–0·68)
0·70 (0·56–0·89)
0·67
(0·41–1·10)
0·81 (0·45–1·45)
0·69
(0·38–1·28)
1·66 (0·56–0·89)
(0·96–2·87)
0·70
0·73 (0·45–1·45)
(0·62–0·86)
0·81

128
p=0·017 for heterogeneity
332
154
67
332
71
154
p=0·331
for heterogeneity
67

71
0·3
p<0·0001 for heterogeneity
0·3
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RR (95% CI)
Linoleic acid
Q1
Q2
Q3
Q4
Q5

1·00 (ref)
0·74 (0·67–0·82)
0·72 (0·65–0·80)
0·67 (0·60–0·74)
0·57 (0·51–0·64)

Arachidonic acid
Q1
Q2
Q3
Q4
Q5

1·00 (ref)
0·94 (0·85–1·05)
0·98 (0·88–1·09)
0·93 (0·84–1·04)
0·93 (0·83–1·04)

0·5

0·6

0·7

0·8

0·9

1·0

1·1

Figure 3: Pooled relative risks of type 2 diabetes per quintile of linoleic acid
and arachidonic acid biomarker
Association of linoleic acid and arachidonic acid levels with type 2 diabetes was
assessed in multivariable models for each cohort, and results were pooled using
inverse-variance weighted meta-analysis. The lowest quintile was used as the
reference group. For studies in which multiple biomarkers were available,
one was chosen for the overall analysis on the basis of its ability to reflect
long-term dietary intake (in the following order of preference): adipose tissue,
phospholipids, total plasma, and cholesterol esters. Similarly, data for
erythrocyte phospholipids was preferable to plasma phospholipids if data on
both biomarkers were available. The Age, Gene/Environment Susceptibility Study
(Reykjavik) was excluded from these analyses due to the small number of patients
who developed incident type 2 diabetes, so the effect estimates were pooled
from the other 19 cohorts. RR=relative risk. Q=quintile.

appreciably reduces the possibility of chance findings or
publication bias, compared with individual cohort reports,
because we included most of the available cohorts with
measured fatty acid biomarkers and assessment of
incident type 2 diabetes. The inclusion of EPIC-InterAct
in our pooled analysis would be unlikely to affect the
conclusions of our study.
Little is known about how differences in fatty acid
function between lipid compartments relate to health. Our
analyses provided novel assessment of dose–response
associations between omega-6 PUFA and type 2 diabetes
in different lipid compartments. For linoleic acid
biomarkers, all compartments (with the exception of
adipose tissue, which was only assessed in one study)
showed significant linear inverse associations with
type 2 diabetes, suggesting a class effect of linoleic acid
rather than primacy of any single compartment. In
exploratory analyses, the protective association between
linoleic acid and type 2 diabetes seemed to be linear
in cholesterol esters and total plasma, but non-linear in
phospholipids, where benefit appeared to plateau at very
high levels. The biological and clinical relevance of this
discrepancy warrants further investigation. Studies are
also needed to define the dose–response relationship
between a broad range of markers of linoleic acid
intake and biomarker concentrations in different lipid
compartments. For arachidonic acid biomarkers, there
was little evidence for non-linearity for any of the lipid
compartments. The opposing associations of erythrocyte
phospholipids and plasma phospholipids with arachi
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donic acid identified by semiparametric analyses require
further investigation; these results could be due to
chance because arachidonic acid concentrations in these
two compartments are highly correlated and are known
to readily interexchange.29 Consistent with this sugges
tion, in the EPIC cohort,28 levels of plasma phospholipid
arachidonic acid were not associated with type 2 diabetes.
Our new findings of a protective association between
arachidonic acid in total plasma and incident type 2
diabetes, based on findings in six cohorts, should be
explored further.
Our investigation has important strengths. We included
prospective cohorts, which minimised the likelihood of
selection bias. Our use of biomarkers avoided recall bias
associated with self-reported intake and allowed objective
assessment of linoleic acid and arachidonic acid levels.
Collaboration between 20 cohorts enabled simultaneous
investigation of multiple lipid compartments, which
could be cost prohibitive in a single study. Harmonised,
predefined analysis protocols standardised exposures,
outcomes, covariates, and statistical modelling, reducing
post-hoc-driven reporting and heterogeneity across
studies. The prespecified analytic plan and inclusion of
20 (77%) of the 26 identified global cohorts greatly
reduced publication bias. The large numbers of partici
pants and events increased statistical power to explore
effect modification. Results were consistent in sensitivity
analyses, increasing confidence in the robustness of
findings and underlying model assumptions. Inclusion
of multiple cohorts and nations with diverse demo
graphic, lifestyle, and dietary characteristics enhanced
generalisability.
Our study also has limitations. Few data were available
on adipose tissue, reducing power and precision to assess
its relevance for type 2 diabetes. Although multiple races
and ethnicities were included, most participants were of
European descent and statistical power was low with
respect to differences in other ethnic groups, although
central risk estimates for linoleic acid biomarkers were
protective in each group. Fatty acid biomarker levels were
assessed at baseline, and changes over time would
attenuate findings toward the null hypothesis, causing
underestimation of magnitudes of true associations.
Linoleic acid biomarkers reflect dietary intake and other
factors such as metabolism, so differences in type 2
diabetes risk should not be interpreted as entirely
attributable to dietary linoleic acid. We did not assess
other fatty acid biomarkers, which should be the subject
of future investigations—particularly saturated fatty acids
such as palmitic acid, which has shown pro-diabetogenic
effects in experimental studies.30–32 In addition, the re
liability of type 2 diabetes ascertainment was likely to
have differed across the cohorts, which might have caused
some outcome misclassification and underestimation
of true associations. Our findings are relevant for the
incidence of type 2 diabetes, but not type 1 diabetes.
Residual confounding by unmeasured or imprecisely
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measured covariates, including by other fatty acid
biomarkers, cannot be fully excluded. However, the mag
nitude of the observed association between linoleic acid
biomarkers and the incidence of type 2 diabetes,
consistency across biomarker compartments, inclusion
of varied popula
tions with diverse underlying charac
teristics, and supportive biological plausibility from inter
ventional trials of risk factors suggest that our findings
are not solely due to statistical chance and uncontrolled
confounding.
In conclusion, this international collaboration of
20 prospective cohorts showed that biomarker levels of
linoleic acid, the major dietary omega-6 PUFA, were
inversely associated with the risk of incident type 2
diabetes, whereas levels of arachidonic acid were not
significantly associated with risk of the disease.
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